On November 19, AKESO rose 3.31% in Regular Trading, trading at HK$60.95, with turnover of HK$558 million.
The clearest recent catalyst is the company’s continued open-market share purchases after approving up to HK$200 million for such transactions, which helped support sentiment following the recent FDA setback for ivonescimab.
Company disclosures show the trustee bought 200,000 shares on November 18 for about HK$12 million, after purchasing 250,000 shares for about HK$16 million on November 17 and 336,000 shares for about HK$21 million on November 16. Management said the purchases reflect confidence in the business outlook and future prospects, with funding from existing cash resources. The rebound comes as investors continue to assess the impact of the FDA complete response letter on ivonescimab and the possibility of additional clinical work.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments